Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study.

Jianming XuYun ZhangRu JiaChunyan YueLianpeng ChangRongrui LiuGairong ZhangChuanhua ZhaoYaoyue ZhangChunxia ChenYan WangXin YiZhiyuan HuJianjun ZouQuanren Wang

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)

SHR-1210 and apatinib combination therapy demonstrated manageable toxicity in patients with HCC and GC/EGJC at recommended single-agent doses of both drugs. The RP2D for apatinib as combination therapy was 250 mg, which showed encouraging clinical activity in patients with advanced HCC.

Keyphrases

combination therapy
papillary thyroid
oxidative stress
open label
randomized controlled trial
squamous cell
clinical trial
young adults
mass spectrometry
double blind